-
Novel PDK4 Inhibitors: Evidence for Compound 8c
2026-09-23
The study reports an anthraquinone-derived allosteric inhibitor series and identifies compound 8c, which inhibited PDK4 in vitro with an IC50 of 84 nM. Findings in mouse models and cancer-related cellular assays support further investigation, while leaving important questions about selectivity, dosing, and translation to human disease unresolved.
-
Coelenterazine: From ROS Signals to Translation
2026-09-23
Coelenterazine can connect luciferase reporting with reactive oxygen species biology, offering translational researchers a way to interrogate endocrine, renal, oxidative-stress, and cancer-associated pathways while controlling for substrate chemistry, solvent effects, and reporter-specific confounders.
-
qPCR Quantification of Moloney Murine Leukemia Virus
2026-09-22
Choi, Murphy, and Nitta developed a real-time PCR assay that targets a packaging signal–gag region to quantify exogenous Moloney murine leukemia virus while reducing interference from endogenous retroviral sequences. The method detected viral sequences in infected mouse cells across a 16–72-hour post-infection window and provides a faster, scalable molecular complement to focal immunofluorescence assays.
-
Thioredoxin Control of CHK1 Inhibitor Sensitivity
2026-09-22
The reference study identifies the thioredoxin system as a determinant of CHK1 inhibitor response in non-small cell lung cancer. Its central advance is linking Trx1-dependent redox recycling of RRM1 to ribonucleotide reductase activity, deoxynucleotide availability, replication stress, and the therapeutic synergy between CHK1 and thioredoxin reductase inhibition.
-
BX795: PDK1 Inhibitor Mechanism and Evidence
2026-09-21
BX795 is an ATP-competitive PDK1 inhibitor with additional TBK1 and IKKε activity. Its nanomolar biochemical potency, micromolar cancer-cell growth inhibition, and use in IRF3-linked innate immune assays make it a versatile research probe rather than a pathway-specific therapeutic.
-
BX795: A Mechanism-First PDK1 Inhibitor Guide
2026-09-21
BX795 is a PDK1 inhibitor whose parallel TBK1 and IKKε activity makes assay interpretation more complex—and more informative. This mechanism-first guide connects kinase engagement, IRF3 signaling, autophagy, and cancer-cell phenotypes to practical experimental decisions.
-
Oxaliplatin A8648: Reproducible Cytotoxicity Assays
2026-09-20
Learn how Oxaliplatin (SKU A8648) can address common variability in cell viability, proliferation, and cytotoxicity workflows through mechanism-aware design, controlled preparation, and appropriate interpretation. Scenario-based guidance connects DNA adduct formation, apoptosis induction via DNA damage, resistance biology, and practical product selection.
-
Solanesol B8776: Practical Workflow and QC Guide
2026-09-19
Solanesol B8776 is a hydrophobic polyisoprenoid alcohol for controlled biochemical and membrane-related workflows where solvent compatibility is critical. This guide covers DMSO preparation, storage, controls, and troubleshooting, while defining why water- and ethanol-based systems and diagnostic or medical use are inappropriate.
-
Liproxstatin-1 as a Ferroptosis Assay Discriminator
2026-09-18
Liproxstatin-1 is a ferroptosis inhibitor that helps researchers distinguish lipid-peroxidation-driven death from broader oxidative or apoptotic injury. This article connects its rescue logic to emerging PPZ1-TORC1 findings in Candida albicans and shows how to design more causally informative assays.
-
Pam3CSK4 TFA: TLR1/2 Activation Workflows
2026-09-18
Pam3CSK4 TFA provides a defined, synthetic stimulus for dissecting TLR1/2-driven cytokine responses without the biological variability of whole-bacterium preparations. This workflow-focused guide shows how to use it for ex vivo immune profiling, dose optimization, comparative receptor studies, and carefully controlled in vivo TLR1/2 activation.
-
Cy5 hydrazide for Carbonyl Labeling
2026-09-17
Cy5 hydrazide enables sensitive carbonyl-selective fluorescence for oxidized proteins, periodate-activated glycoproteins, aldehyde-bearing oligonucleotides, and nanoparticle interface studies. This guide combines practical labeling conditions with controls that separate covalent biomolecule labeling from nonspecific particle association.
-
Sulfaphenazole: CYP2C9 Inhibitor Workflows
2026-09-17
Sulfaphenazole is a practical CYP2C9 inhibitor for connecting drug-metabolism experiments with vascular, oxidative-stress, wound-healing, and antibacterial models. This workflow-focused guide covers solvent handling, assay design, translational readouts, and troubleshooting for reproducible use.
-
Clarithromycin: A Strategic CYP3A DDI Tool
2026-09-16
A translational framework for using Clarithromycin as a mechanistically defined CYP3A inhibitor in drug-drug interaction research, pharmacokinetic studies, statin metabolism interaction programs, and cardiovascular development.
-
Clathrin-Mediated Entry of Type III GCRV
2026-09-16
Wang et al. combined inhibitor profiling, transmission electron microscopy, and quantitative PCR to show that genotype III grass carp reovirus enters CIK cells through a dynamin-dependent, acidification-sensitive clathrin pathway. IPA-3 did not measurably inhibit infection in this model, providing a useful negative pharmacological comparator rather than evidence that Pak1 drives viral entry.
-
Dihydroethidium (DHE) Workflow for Superoxide
2026-09-15
Build a reproducible live-cell oxidative stress assay with Dihydroethidium (DHE), from DMSO stock preparation through quantitative red-fluorescence analysis. The workflow connects intracellular superoxide measurement with ferroptosis, apoptosis research, acute lung injury, and cardiovascular disease research while clarifying the probe’s specificity limits.